AU2007249281A1 - Anticancer treatments with a combination of docetaxel and ecteinascidin - Google Patents

Anticancer treatments with a combination of docetaxel and ecteinascidin Download PDF

Info

Publication number
AU2007249281A1
AU2007249281A1 AU2007249281A AU2007249281A AU2007249281A1 AU 2007249281 A1 AU2007249281 A1 AU 2007249281A1 AU 2007249281 A AU2007249281 A AU 2007249281A AU 2007249281 A AU2007249281 A AU 2007249281A AU 2007249281 A1 AU2007249281 A1 AU 2007249281A1
Authority
AU
Australia
Prior art keywords
docetaxel
administered
cancer
dose
infusion time
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007249281A
Other languages
English (en)
Inventor
Yusri Ali Elsayed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of AU2007249281A1 publication Critical patent/AU2007249281A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007249281A 2006-05-12 2007-05-11 Anticancer treatments with a combination of docetaxel and ecteinascidin Abandoned AU2007249281A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80051006P 2006-05-12 2006-05-12
US60/800,510 2006-05-12
PCT/US2007/068727 WO2007134203A2 (en) 2006-05-12 2007-05-11 Anticancer treatments with a combination of docetaxel and ecteinascidin

Publications (1)

Publication Number Publication Date
AU2007249281A1 true AU2007249281A1 (en) 2007-11-22

Family

ID=38596836

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007249281A Abandoned AU2007249281A1 (en) 2006-05-12 2007-05-11 Anticancer treatments with a combination of docetaxel and ecteinascidin

Country Status (7)

Country Link
US (1) US20100009906A1 (enExample)
EP (1) EP2023931A2 (enExample)
JP (1) JP2009536956A (enExample)
AU (1) AU2007249281A1 (enExample)
CA (1) CA2652035A1 (enExample)
MX (1) MX2008014404A (enExample)
WO (1) WO2007134203A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
WO2002036135A2 (en) * 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
RS50822B (sr) * 2004-10-26 2010-08-31 Pharma Mar S.A., Sociedad Unipersonal Pegilovani lipozomalni doksorubicin u kombinaciji sa ekteinescidinom 743
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
WO2009050303A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for et-743 treatment
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
WO2002036125A1 (en) * 2000-10-31 2002-05-10 Head Explorer A/S The use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
PL368458A1 (en) * 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy

Also Published As

Publication number Publication date
WO2007134203A3 (en) 2008-05-29
JP2009536956A (ja) 2009-10-22
WO2007134203A2 (en) 2007-11-22
MX2008014404A (es) 2008-11-27
CA2652035A1 (en) 2007-11-22
US20100009906A1 (en) 2010-01-14
EP2023931A2 (en) 2009-02-18

Similar Documents

Publication Publication Date Title
US20100009906A1 (en) Anticancer Treatments
EP2637663B1 (en) Combination therapy with an antitumor alkaloid
RU2587013C2 (ru) Комбинированная химиотерапия
US8927530B2 (en) Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
US20220000835A1 (en) Method for treating cancer with a combination of quercetin and a chemotherapy agent
BG107843A (bg) Ефективно антитуморно лечение
RU2306933C2 (ru) Улучшенная схема применения противоопухолевого соединения в терапии рака
US20110015135A1 (en) Antitumoral Treatments
JP2003533485A5 (enExample)
CN1507869A (zh) 含吗啉蒽环类化生物和抗癌剂的联合制剂
HUP0500478A2 (hu) Taxánszármazékokat tartalmazó tumorellenes készítmények
ZA200509600B (en) Combined use of ecteinascidin-743 and platinum antineoplastic compounds
US20080255132A1 (en) Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
Aapro et al. Developments in cytotoxic chemotherapy: advances in treatment utilising vinorelbine
WO2008135793A1 (en) Combination of aplidine and carboplatin in anticancer treatments
WO2008135792A1 (en) Pm00104 compound for use in cancer therapy
Akerley Recent developments in weekly paclitaxel therapy in lung cancer
ZA200508696B (en) Use of irinotecan for treatment of resistant breast cancer
NZ513352A (en) Anti-tumor synergetic composition
MXPA06005359A (en) Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
HK1188572B (en) Combination therapy with an antitumor alkaloid
HK1202419B (en) Combination therapy with a mitotic inhibitor
HK1202423B (en) Combination therapy with a topoisomerase inhibitor
HK1202421B (en) Combination therapy with an antitumor antibiotic
MXPA05003625A (es) Terapia de combinacion con gencitabina y zd6126.

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application